The Equity Incentive Plan Has Been Set Down By &Nbsp; The Eye Market Is Located In The Northwest Market.

"The company strives to complete the distribution of eye hospital in all the provincial capitals within two years, and build a prefecture level city hospital in Hunan and Hubei, and then distribute the prefecture level cities in other provinces in three years." At the annual shareholders' meeting held in May 6th at El eye (300015), Chen Bang, chairman of the company, described the domain of AI ophthalmology. According to the disclosure, AI ophthalmology last year Investment 10 hospitals will reinvest 10 this year, but the scale will be slightly smaller than last year. The next expansion target of the company will be in Northwest China.

At the shareholders' meeting, the eye eye equity incentive plan passed smoothly. The cost amortization expense due to option incentive will be counted annually. list The cost of the company will result in Book pressure on the company's profit statement in the next few years. "However, this amortization pressure is lower than we originally thought, and originally thought that 1 billion, but now it seems that tens of millions of yuan is enough." Chen Bong explained that the company originally estimated that the stock price would be more than 39 yuan, but its share price was only 35 yuan. "The cost amortization of the company is expected to be 12 million yuan in 2011 and 17 million yuan in 2012." Based on the 2010 net profit of 120 million yuan in El eye, the average annual net profit growth of 30%~50% per year was calculated. The cost amortization pressure of equity incentive is not too great.

" stock right Incentives are conducive to the stability of core management teams and technical teams, especially in the high-technology industries such as ophthalmic care. Equity incentive is of great significance for maintaining excellent talents. Wang Xi, an analyst at Xingye securities, said that the eye is willing to encourage prices at a price higher than the current two level market share, which means that management has confidence in the future performance.

Following the merger of 6 hospitals in Beijing, such as Ying Zhi, Chenzhou Guangming and Tianjin MEG in 2010, the company completed the acquisition and purchase of Xi'an ancient eye hospital in the first quarter of 2011, holding 70% of the latter, and invested 18 million 600 thousand yuan to Chongqing Macquarie in the way of capital expansion and expansion. It is revealed that the acquisition of MCG ophthalmology in Chengdu is coming to an end.

Preliminary statistics show that after the acquisition of Xi'an ancient Eye Hospital, the number of eye hospital chain has increased to 33, with 20 provinces, municipalities and 12 prefecture level cities.

"The next step for the company is to complete the layout of the northwest capital market." Chen Bang said that several capital cities in Northwest China, including Lanzhou and Xinjiang, have been incorporated into the expansion area of AI eye department, but he did not disclose specific targets.

As for the future expansion of AI eye, Chen Bong said that he would walk on two legs with "acquisition and new construction". The choice of M & A targets mainly considered market layout, technical complementarity and purchase price.

In addition to making eye on the layout of ophthalmic hospitals, Eyre ophthalmology will also work in the lens business. Statistics show that in the market of ophthalmic medical services, ophthalmology and medical care and spectacle business each take up half of the country. The 2010 annual report of Eyre ophthalmology shows that the gross profit margin of the company's mirror business is as high as 59%. Li Li, President of eyel eye, revealed that the company is currently training optometrists, trial masters and trial doctors at three levels, which is a talent for future acquisitions and mergers.